Syndax Pharmaceuticals, Inc.
NASDAQSNDX short interest falls 20% in one week to 19.9% of float, yet remains elevated as cost-to-borrow stays subdued at 0.42%.
Snapshot as of 23 Jun 2026
Syndax Pharmaceuticals enters the back half of May with one of the highest short burdens in small-cap biotech — yet the analysts covering it remain uniformly bullish, pointing to a gap between positioning and…
Syndax Pharmaceuticals arrives at its May 5 investor event carrying fresh wounds — a Q1 revenue miss, an 11% single-day drop, and short interest at 24% of the free float. Short sellers are deeply dug in. At 24.1% of…
Syndax Pharmaceuticals reports Q1 2026 results after market close today, entering the print with its stock down 6.6% on the week and 12% over the past month — back to prices last seen before a brief rally this spring.…
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for SNDX — free to start on ORTEX.
Sign up for free →Open SNDX on ORTEX